Inappropriate regulation of a variety of signal transduction processes can result in a multitude of diseases due to improper differentiation and development or malignant transformation. PI3K plays a critical role in cell proliferation. Until recently, however, little was known regarding how PI3K signaled. P70S6K1 was the first signaling protein kinase shown to act downstream of PI3K. Since then, S6K1 activation has been shown to require several lipid-dependent kinases, binding to activated rho family G proteins (Cdc42/rac1), and phosphorylation at multiple sites by distinct inputs. Underscoring its importance, oncogene products such as Dbl, TIAM-1, and Akt specifically activate S6K1, and the T cell immunosuppressants rapamycin and dexamethasone specifically antagonize its activation. The two isoforms of S6K1, alpha-1 and alpha-2, are believed to regulate gene expression and protein translation, respectively. However, little is known of their downstream targets. The research proposed in this application addresses issues regarding the regulation of S6K1 activation, downstream signaling and its role in cell proliferation. The first objective is to define the mechanisms of S6K1 activation by determining how phosphorylation of the autoinhibitory domain and two critical sites in the linker region, S371 and T389, are regulated, and the consequences of these phosphorylations to S6K1 activation. In addition, how these events are coordinated with and cooperate with the phosphorylation of T229 in the activation loop by PDK1 will be examined. The second objective is to identify, using molecular and biochemical approaches, S6K1 associated proteins and assess their roles in regulation of S6K1 or signaling by S6K1. These proteins are expected to be either upstream regulators, downstream targets, or scaffolding proteins that assemble the S6K1 signaling complex. The third objective is to characterize the biological function of S6K1 in a cell system that will allow elucidation of the linkage between S6K1 and the cell cycle machinery. The fourth objective is to characterize transgenic mice expressing S6K1 in a transgenic T-cell model, to assess the role of the protein kinase in murine T-cell proliferation, differentiation, and ultimately function. Since several hematopoietic oncogenes and T cell immunosuppressants modulate S6K1 activity this will allow the examination of the functions of S6K.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM051405-05A1
Application #
6133569
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Marino, Pamela
Project Start
1995-09-01
Project End
2004-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
5
Fiscal Year
2000
Total Cost
$449,809
Indirect Cost
Name
Harvard University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
He, Long; Gomes, Ana P; Wang, Xin et al. (2018) mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation. Mol Cell 70:949-960.e4
Schild, Tanya; Low, Vivien; Blenis, John et al. (2018) Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization. Cancer Cell 33:347-354
Gomes, Ana P; Schild, Tanya; Blenis, John (2017) Adding Polyamine Metabolism to the mTORC1 Toolkit in Cell Growth and Cancer. Dev Cell 42:112-114
Yoon, Sang-Oh; Shin, Sejeong; Karreth, Florian A et al. (2017) Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Mol Cell 67:512-527.e4
Lee, Gina; Zheng, Yuxiang; Cho, Sungyun et al. (2017) Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling. Cell 171:1545-1558.e18
Wada, Shogo; Neinast, Michael; Jang, Cholsoon et al. (2016) The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue. Genes Dev 30:2551-2564
Li, Jing; Shin, Sejeong; Sun, Yang et al. (2016) mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress. Cancer Res 76:4816-27
Li, Jing; Csibi, Alfredo; Yang, Sun et al. (2015) Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc Natl Acad Sci U S A 112:E21-9
Shin, Sejeong; Buel, Gwen R; Wolgamott, Laura et al. (2015) ERK2 Mediates Metabolic Stress Response to Regulate Cell Fate. Mol Cell 59:382-98
Gomes, Ana P; Blenis, John (2015) A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. Curr Opin Biotechnol 34:110-7

Showing the most recent 10 out of 34 publications